 |
| |
|
|
| |
Before we can explain about your condition, it is important to understand how the eye works when it is working properly.
For our new patients:
Click here for our medical history questionnaire so we can better assist you on your first visit.
|
|
| |
|
|
|
|
|
|
 |
 |
| |
|
|
| |
|
|
| |
|
|
| |
Here is a list of all the studies in which we are participating or have participated at Retina Specialists. Please call our office at 410-296-9748 for more information.
Current Studies:
Age-related Macular Degeneration (wet)
| LEVEL Study/OSI – EyeTech |
Phase IV – Enrolling |
| CLEAR-IT Study/Regeneron |
Phase III – Upcoming |
| COBALT Study/OPKO |
Phase III – Upcoming |
Diabetic Retinopathy
RISE Study/Genentech, Inc. |
Phase III – Upcoming |
Previous Studies:
Age-related Macular Degeneration (wet)
| HORIZON Study/Genentech, Inc. |
Open Label – Follow-up |
| SAILOR Study/Genentech, Inc. |
Phase IIIb – Follow-up |
| ACUITY Pharmaceuticals |
Phase I – Follow-up |
| CARE Study/ACUITY Pharmaceuticals |
Phase II – Follow-up |
| GENAERA 208 & 209 |
Phase II – Closed |
| GENAERA 301 |
Phase III – Closed |
| MARINA Study/Genentech, Inc. |
Phase III – Closed |
| ANCHOR Study/Genentech, Inc |
Phase III – Closed |
| VIO Study/Novartis |
Phase III – Closed |
| VIO-OLS Study/Novartis |
Open Label – Closed |
| Visudyne Study/CIBA Pharmaceuticals |
Closed |
Diabetic Retinopathy
| PKC Study (MBDV)Extension/Eli Lilly |
Open Label – Follow-up |
| PKC Study (MBCM)/Eli Lilly |
Phase III – Closed |
| RACE Study/Acuity Pharmaceuticals |
Phase II – Follow-up |
| DRCR Study/Laser for Diabetic Macular Edema |
Closed |
Retinal Vein Occlusions
| Posurdex Study/Allergan |
Phase III – Closed |
| Branch Retinal Vein Occlusion |
Pilot Study – Closed |
Nonclearing Vitreous Hemorrhage
| Hyaluronidase/Advanced Corneal Systems, Inc. |
Phase III – Closed |
| Hyaluronidase/Advanced Corneal Systems, Inc. |
Phase II – Closed |
Please contact our office at 410-296-9748 if you are interested in learning more about the latest clinical studies.

|
|
|
| |
|
|
|
|